GE Healthcare




# Using the parallel configuration of Biacore<sup>™</sup> 8K for efficient characterization of monoclonal antibodies

Åsa Sporrong, Linnéa Nygren Babol, Anna Moberg, and Anita Larsson

GE Healthcare Bio-Sciences AB, SE-75184 Uppsala, Sweden

#### Introduction

In this study, the possibilities of the parallel configuration of Biacore 8K (16 flow cells in 8 channels) for efficient reagent characterization was explored. As a model system, six different mouse monoclonal antibodies (mAbs) against recombinant GST (recGST) were tested and compared to a reference antibody.



#### Conclusions

• The parallel configuration of Biacore 8K enabled significant time savings in analyses of binding characteristics, activity, purity, and regeneration of mAb candidates.


The flexibility of 16 flow cells enables a customized assay set-up for each run. It is possible to group the runs as seperate activities in the *Activity queue* and execute them consecutively. The decision on selection of candidate mAbs and setup of the next activity in the *Activity queue* is taken after completion of the previous.

The reference antibody is a capture reagent for GST-tagged proteins and is used immobilized to a sensor chip.

- Flexible use of 16 flow cells allowed all analyses to be performed on a single chip.
- A mAb clone with binding characteristics against recGST and activity similar to the reference antibody was identified. However, the mAb was in an impure state.


#### **Experimental overview**

The flexible, parallel approach included 11 runs grouped in 6 separate consecutive activities in the *Activity queue*, each having a decision point after completion.




#### 3 Test binding capacity on immobilized mAb

Amine coupling of mAb 1 and 6 at pH 5.0 (run 5) and testing of the max binding capacity of mAb 1, mAb 6 and reference antibody (run 6)




Stable binding, but low binding ratios were observed for both mAbs. Low activity/purity was suspected, confirming the results from run 4. → A decision to investigate purity was taken. mAb 1 was selected for further studies.

#### (4) Test purity of mAb preparation



Purity check using immobilized anti-subclass reagents. Injection of mAb 1 followed by recGST (run 8)




The presence of contaminating antibodies was confirmed. mAb 1 (of IgG<sub>1</sub> subtype) proved to be very promising demonstrating similar binding ratio as reference antibody (1.04).

→ A decision to test an approach to selectively immobilize mAb 1 from the impure preparation was taken.

## **1** Test of binding properties

Binding test of reference antibody (run 2)

Binding stability testing of mAb 1 to 6 on Mouse Antibody Capture Kit (run 3)




Stable binding, but low responses compared to the reference antibody was observed for all 6 mAbs.

 $\rightarrow$  mAb 1 and 6 were selected for further testing.

## 5 Test binding capacity on immobilized mAb


Immobilization of mAb 1 at different pH to test if mAb 1 can be selectively immobilized and enriched at a certain pH (run 9). Testing was made by injections of recGST (run 10)



The selective immobilization approach was successful and the best binding capacity was obtained for mAb immobilized at pH 5.5. → Immobilization at pH 5.5 was selected for further testing of mAb 1.

# 2 Test of conditions for immobilization

pH-scouting of mAb 1 and mAb 6 (run 4)




An atypical behavior was observed for both mAbs, indicating impure protein preparations. This was suspected to be due to contaminating polyclonal antibodies potentially originating from the manufacturing method.

→ pH 5.0 was chosen for immobilization of both mAb 1 and 6.

6 Regeneration scouting

Regeneration scouting with 10 mM glycine pH 3.0, 2.5, 2.0, and 1.5 (run 11)



None of the tested conditions worked well (note: starting level for recGST response [505 RU] is in run 10)

 $\rightarrow$  regeneration must be further optimized

GE, GE monogram, and Biacore are trademarks of General Electric Company. © 2016 General Electric Company. First published Jun. 2016. All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information. GE Healthcare Bio-Sciences Corp., 100 Results Way, Marlborough, MA 01752, USA. For local office contact information, visit gelifesciences.com/contact 29215083 AA 06/2016